Evidence map›Paper›PMID 40266224›Full record

ArticleVaccines2025

An mRNA Vaccine for Herpes Zoster and Its Efficacy Evaluation in Naïve/Primed Murine Models.

Linglei Jiang, Wenshuo Zhou, Fei Liu, Wenhui Li, Yan Xu, Zhenwei Liang, Man Cao, Li Hou, Pengxuan Liu, Feifei Wu and 8 more

Abstract read
In one paragraph

Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Linglei JiangCNBG-Virogin Biotech (Shanghai) Co., Ltd., Shanghai 201800, China.
Wenshuo ZhouCNBG-Virogin Biotech (Shanghai) Co., Ltd., Shanghai 201800, China.ORCID 0000-0002-2820-2507
Fei LiuCNBG-Virogin Biotech (Shanghai) Co., Ltd., Shanghai 201800, China.
Wenhui LiCNBG-Virogin Biotech (Shanghai) Co., Ltd., Shanghai 201800, China.ORCID 0009-0007-7208-5639
Yan XuCNBG-Virogin Biotech (Shanghai) Co., Ltd., Shanghai 201800, China.
Zhenwei LiangCNBG-Virogin Biotech (Shanghai) Co., Ltd., Shanghai 201800, China.
Man CaoCNBG-Virogin Biotech (Shanghai) Co., Ltd., Shanghai 201800, China.
Li HouCNBG-Virogin Biotech (Shanghai) Co., Ltd., Shanghai 201800, China.ORCID 0009-0003-0151-4046
Pengxuan LiuCNBG-Virogin Biotech (Shanghai) Co., Ltd., Shanghai 201800, China.
Feifei WuCNBG-Virogin Biotech (Shanghai) Co., Ltd., Shanghai 201800, China.
Aijun ShenCNBG-Virogin Biotech (Shanghai) Co., Ltd., Shanghai 201800, China.
Zhiyuan ZhangCNBG-Virogin Biotech (Shanghai) Co., Ltd., Shanghai 201800, China.
Xiaodi ZhangCNBG-Virogin Biotech (Shanghai) Co., Ltd., Shanghai 201800, China.
Haibo ZhaoCNBG-Virogin Biotech (Shanghai) Co., Ltd., Shanghai 201800, China.
Xinping PanCNBG-Virogin Biotech (Shanghai) Co., Ltd., Shanghai 201800, China.
Tengjie WuCNBG-Virogin Biotech (Shanghai) Co., Ltd., Shanghai 201800, China.
William JiaCNBG-Virogin Biotech (Shanghai) Co., Ltd., Shanghai 201800, China.ORCID 0000-0002-2755-6821
Yuntao ZhangSinopharm Group China National Biotech Group (CNBG) Co., Ltd., Beijing 100124, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

herpes zosterimmunogenicityintradermal administrationlyophilizationmRNA vaccine

Identifiers

PMID40266224
PMCPMC11946168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.